As part of our series focussing on medicines in Australia, we have added a product review of the use of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide for management of stable COPD.
This publication focuses on single inhaler extrafine beclometasone dipropionate, formoterol fumarate and glycopyrronium for maintenance treatment in adults with moderate to severe COPD who are not adequately controlled with dual therapy. It provides commentary from Dr Andrew Scroop, Director of Respiratory Consultants, St Andrews Medical Centre, Adelaide.
Please login below to download this issue (PDF)